High Purity Trans-4-Isopropylcyclohexane Carboxylic Acid: Pharmaceutical Intermediate Manufacturer & Supplier in China

Discover Trans-4-Isopropylcyclohexane Carboxylic Acid (CAS: 7077-05-6), a critical raw material and pharmaceutical intermediate for Nateglinide, a leading hypoglycemic agent for Type 2 Diabetes. We, as a leading manufacturer and supplier in China, offer high purity (≥99.30%) material with competitive pricing. Contact us for your bulk purchase and custom packaging needs.

Get a Quote & Sample

Advantages of Sourcing from Our China Manufacturer

Stringent Quality Control & Assay

Our Trans-4-Isopropylcyclohexane Carboxylic Acid consistently meets ≥99.30% assay, verified through rigorous GC testing, ensuring the highest standards for your pharmaceutical intermediates. Buy with confidence from our reliable supplier.

Expertise in Pharmaceutical Intermediates

Leveraging years of experience, we specialize in producing critical intermediates like CAS 7077-05-6. Our deep understanding of pharmaceutical synthesis allows us to offer tailored solutions and technical support.

Competitive Pricing and Global Reach

We offer competitive price points for Trans-4-Isopropylcyclohexane Carboxylic Acid, making us an ideal supplier for global pharmaceutical companies seeking cost-effective raw materials from China.

Key Applications in Pharmaceutical Synthesis

Nateglinide Synthesis

The primary application is as a crucial intermediate in the multi-step synthesis of Nateglinide, an insulin secretagogue used to treat type 2 diabetes.

Diabetes Treatment R&D

Supports ongoing research and development efforts in new diabetes therapies by providing a high-quality building block for novel drug candidates.

Chiral Synthesis Applications

Its trans configuration and carboxylic acid functionality make it valuable in chiral synthesis and as a precursor for developing chiral resolving agents.

Fine Chemical Intermediate

Serves as a versatile intermediate in the broader fine chemical industry, enabling complex organic synthesis pathways beyond pharmaceutical applications.